{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cellulitis-acute/prescribing-information/clarithromycin/","result":{"pageContext":{"chapter":{"id":"73060223-dd90-59da-bae3-c706b5d24298","slug":"clarithromycin","fullItemName":"Clarithromycin","depth":2,"htmlHeader":"<!-- begin field 88e7012d-d474-4a69-8891-7ba292e1c0d1 --><h2>Clarithromycin</h2><!-- end field 88e7012d-d474-4a69-8891-7ba292e1c0d1 -->","summary":"","htmlStringContent":"<!-- begin item cad8a75f-d9f9-403d-9bbe-0bd6d25bda4c --><!-- end item cad8a75f-d9f9-403d-9bbe-0bd6d25bda4c -->","topic":{"id":"c0841d82-0a64-5b27-81dc-9a825d85f1bf","topicId":"6db61277-29ef-49cc-bad1-d0d78d0afc10","topicName":"Cellulitis - acute","slug":"cellulitis-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"84376fdb-da2b-561d-bb40-28b5b1a7e975","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bdf35905-533d-5cb1-bd18-9c1575427a25","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d6c8c4bd-9395-5840-83c7-67ddfeabdf85","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"59d003f6-dd50-5136-b5c2-c2ea4e4b6f01","slug":"changes","fullItemName":"Changes"},{"id":"f79ca51e-9432-56b1-95de-92ed6133be2b","slug":"update","fullItemName":"Update"}]},{"id":"05002b30-8200-5ccf-b9da-7c96acdb65bd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fefb70b6-1d32-5e70-afc6-291fa40b3137","slug":"goals","fullItemName":"Goals"},{"id":"cf84220a-f381-5ca1-aa76-ffb99c4959f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aa32cbb7-29d6-58b6-bcde-7702767672ec","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7e039433-2afe-5980-93f0-c20c41976610","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d1411fdd-dc83-5f20-9fa4-ad67b69c195a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ce40a600-51e8-5b3a-86c2-d127f03c16eb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ff60c523-3d6f-5766-8508-98e8cdcf08f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8e8cfe4a-13f2-573c-ab45-7231016746c4","slug":"definition","fullItemName":"Definition"},{"id":"2b7befe3-0fef-5d4e-b00d-bad6742fb93c","slug":"causes","fullItemName":"Causes"},{"id":"96971948-f52b-561c-84f8-8600f3eff2d4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4749dc8a-3f24-5e65-a0a3-5d7665ef3085","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ad3d41f6-595b-505c-b020-918f0e086d3f","slug":"complications","fullItemName":"Complications"},{"id":"82ccb916-06d4-5b29-91e4-90005f3db942","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7305e6df-9b2c-5584-9412-54564432e382","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8625eea6-53ec-5348-befa-a609ea64590f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"273b1216-536e-59b4-8c39-547a97824ffa","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"68b86e3a-ee13-5ccd-9df0-a5c70c553251","fullItemName":"Management","slug":"management","subChapters":[{"id":"195394ca-067a-5cf3-bc4d-52a189d2cba6","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"4426193a-52c1-59b9-9222-77fb7169a3d1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"78de19b8-8e80-551f-8112-456ce2e25bb0","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"73060223-dd90-59da-bae3-c706b5d24298","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"83f47301-e112-5f78-a79a-5c03a9de9537","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"b7240858-fbcc-5f20-8dcd-19f0b7221ac4","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07828388-33ed-5e04-90b7-28a76fa26c6e","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"4600d0c1-4cd1-51ee-87a0-b660f0fa2165","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"0c0b7a3f-11e4-5b00-bd21-b66e49f9ad77","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"29987f8b-20b6-5c1f-8d23-183b415a04fb","slug":"analgesia","fullItemName":"Analgesia"}]},{"id":"4b09dc1a-8268-50d6-a164-227a73b3556e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d49b86e1-77b2-58e6-82c0-ea0aa7ee74ed","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fe910063-69df-5218-bb78-36f5863db2a1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"129f5233-2934-55ad-a561-4eb37861dc10","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"74d5b6b4-ef9d-5fc4-b41b-656b81a7ded8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"44402335-ffeb-5e14-9e77-bb8278ef43d6","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"04d7d640-f586-53d9-ac59-804c10dd593d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c50af1ff-f157-5023-92b4-aa07b1c28d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4426193a-52c1-59b9-9222-77fb7169a3d1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"e682db20-6ab9-5bfc-91b9-90f116910d5e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 1ea8e6f7-f6f5-4d85-bf04-b216197ad107 --><h3>What are the contraindications and cautions for clarithromycin?</h3><!-- end field 1ea8e6f7-f6f5-4d85-bf04-b216197ad107 -->","summary":"","htmlStringContent":"<!-- begin item 83ce341e-7be4-4185-85b7-e90cf7e647cc --><!-- begin field 68e0c3b7-daa2-455b-9169-ddc3584646f5 --><ul><li><strong>Do not prescribe </strong><strong>clarithromycin </strong>to:<ul><li>People with:<ul><li>Severe hepatic impairment in combination with renal impairment.</li><li>Hypokalaemia.</li><li>A history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de pointes arrhythmias.</li></ul></li><li>Pregnant or breastfeeding women (unless potential benefit outweighs risk). See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/prescribing-information/clarithromycin/#pregnancy-breastfeeding\">Pregnancy and breastfeeding</a> for more information.</li></ul></li><li><strong>Prescribe clarithromycin with caution </strong>to:<ul><li>People with:<ul><li>Impaired hepatic function — clarithromycin is principally excreted by the liver. Hepatic dysfunction including increased liver enzymes and cholestatic hepatitis (with or without jaundice) has been rarely reported with its use.</li><li>Conditions which predispose to QT interval prolongation, such as electrolyte disturbances — macrolides can also prolong the QT interval, increasing the risk of Torsades de pointes arrhythmias.</li><li>Chronic kidney disease (CKD) stages 4 and 5 — if the estimated glomerular filtration rate (eGFR) is less than 30 mL/minute/1.73 m<sup>2</sup>, prescribe half the normal dose, and avoid Klaricid XL<sup>®</sup> or clarithromycin M/R preparations. </li><li>Coronary artery disease, severe cardiac insufficiency, or bradycardia (heart rate less than 50 beats per minute) — increased risk of QT prolongation.</li><li>Myasthenia gravis — clarithromycin may aggravate symptoms.</li></ul></li><li>People concomitantly taking:<ul><li>Potentially hepatotoxic drugs — clarithromycin is principally excreted by the liver. Hepatic dysfunction including increased liver enzymes and cholestatic hepatitis (with or without jaundice) has been rarely reported with its use.</li><li>Drugs that prolong the QT interval, for example amiodarone, sotalol, and amisulpride — macrolides can also prolong the QT interval, increasing the risk of Torsades de pointes arrhythmias.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 68e0c3b7-daa2-455b-9169-ddc3584646f5 --><!-- end item 83ce341e-7be4-4185-85b7-e90cf7e647cc -->","subChapters":[]},{"id":"5035e379-dbe8-5082-8c76-558e8bf23b46","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field e15a3037-70fc-406b-bf41-830858ec1c1b --><h3>What are the possible adverse effects of clarithromycin?</h3><!-- end field e15a3037-70fc-406b-bf41-830858ec1c1b -->","summary":"","htmlStringContent":"<!-- begin item 05684b78-5e34-4a32-a44f-836a99aa387e --><!-- begin field d252bc99-4d0e-4503-8982-8b5b777b1553 --><ul><li><strong>The most common adverse effects of clarithromycin include </strong>abdominal pain, nausea, vomiting, taste perversion, and diarrhoea. <ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with clarithromycin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Reversible hearing loss (sometimes with tinnitus) </strong>can occur after large doses of clarithromycin.</li><li><strong>Other adverse effects of macrolides, including clarithromycin, include:</strong><ul><li>Common or very common — decreased appetite, dizziness, gastrointestinal discomfort, gastrointestinal disorders, headache, hearing impairment, insomnia, pancreatitis, paraesthesia, skin reactions, vasodilation, and vision disorders.</li><li>Uncommon — angioedema, anxiety, arrhythmias, burping, candida infection, chest pain, constipation, drowsiness, dry mouth eosinophilia, epistaxis, hepatic disorders, leucopenia, muscle complaints, neutropenia, oral disorders, palpitations, QT interval prolongation, severe cutaneous adverse reactions (SCARs), thrombocytosis, tremor, and vertigo.</li><li>Rare or very rare —<strong> </strong>myasthenia gravis, nephritis tubulointerstitial.</li><li>Frequency not known — abnormal dreams, agranulocytosis, altered smell, depersonalisation, depression, hallucination, hypotension, mania, myopathy, psychotic disorder, renal failure, seizure, thrombocytopenia, tongue discolouration, tooth discolouration, and urine discolouration.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field d252bc99-4d0e-4503-8982-8b5b777b1553 --><!-- end item 05684b78-5e34-4a32-a44f-836a99aa387e -->","subChapters":[]},{"id":"63970a58-4231-55bc-ac7e-f2b0502104d0","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 1530cd53-b915-4a85-9d86-0d2e77d45fa5 --><h3>What are the possible drug interactions of clarithromycin?</h3><!-- end field 1530cd53-b915-4a85-9d86-0d2e77d45fa5 -->","summary":"","htmlStringContent":"<!-- begin item 9de11e99-0c5f-4956-9f75-44f87b635ecf --><!-- begin field b13479b5-3a47-4ad7-9f7c-0037fc2ede41 --><ul><li><strong>Drug interactions of clarithromycin include:</strong><ul><li><strong>Aminophylline</strong> — be aware that aminophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with clarithromycin.</li><li><strong>Calcium channel blockers (CCBs)</strong> — clarithromycin possibly inhibits the metabolism of CCBs, increasing the risk of adverse effects, such as hypotension.</li><li><strong>Carbamazepine </strong>— clarithromycin can increase carbamazepine levels, causing carbamazepine toxicity (which may present as nausea and vomiting, ataxia, and drowsiness).<ul><li>Monitor carbamazepine levels within 3–5 days of starting clarithromycin, and adjust dose accordingly. </li></ul></li><li><strong>Colchicine </strong>— clarithromycin possibly increases the risk of colchicine toxicity.<ul><li>Stop or reduce the dose of colchicine.</li><li>Avoid concomitant use in renal or hepatic impairment.</li></ul></li><li><strong>Drugs that prolong the QT interval</strong> (such as amiodarone, amisulpride, fluconazole, sildenafil, and tricyclic antidepressants) — macrolides can also prolong the QT interval, increasing the risk of arrhythmias (such as Torsades de pointes).<ul><li>Concurrent use of drugs that prolong the QT interval is not recommended.</li></ul></li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, short-acting beta-2 agonists) — hypokalaemia is a risk factor for QT prolongation.</li><li><strong>Digoxin</strong> — clarithromycin increases the concentration of digoxin. <ul><li>Monitor digoxin concentration.</li></ul></li><li><strong>Ergotamine and dihydroergotamine </strong>— concurrent use with clarithromycin may result in acute ergot toxicity. <ul><li>Concurrent use is contraindicated.</li></ul></li><li><strong>Oral hypoglycaemic drugs and insulin </strong>— concurrent use of clarithromycin and antidiabetic drugs (such as sulphonylureas and/or insulin) can result in significant hypoglycaemia.<ul><li>Monitor blood glucose levels more regularly, and adjust the antidiabetic drug (and/or insulin) dose accordingly. </li></ul></li><li><strong>Statins </strong>— there is an increased risk of myopathy (due to cytochrome P450 enzyme CYP3A4 inhibition) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">MHRA, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">MHRA, 2014</a>].   <ul><li>For simvastatin (potent CYP3A4 inhibitor) — concurrent use is contraindicated. If clarithromycin treatment cannot be avoided, stop treatment with simvastatin during the course of the treatment.</li><li>For atorvastatin (moderate CYP3A4 inhibitor) — avoid concurrent use if possible. If clarithromycin treatment cannot be avoided, stop treatment with simvastatin during the course of the treatment or prescribe the lowest starting dose of atorvastatin (that is 10 mg) and do not exceed 20 mg atorvastatin daily. Advise the person to seek medical advice if they experience symptoms of myopathy (for example muscle pain, tenderness, or weakness).</li><li>For pravastatin — prescribe clarithromycin with caution, and advise the person to report any muscle pain, tenderness, or weakness.</li><li>Other statins — rosuvastatin is not associated with cytochrome P450 interactions, and clinically significant interaction with clarithromycin is not expected for fluvastatin. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness. </li></ul></li><li><strong>Theophylline </strong>— clarithromycin possibly increases the plasma concentration of theophylline.<ul><li>Consider a dose reduction of theophylline if toxicity is suspected (for example if headache, nausea, or palpitations occur).</li></ul></li><li><strong>Quetiapine </strong>— clarithromycin possibly increases the plasma concentration of quetiapine.<ul><li>Avoid concurrent use.</li></ul></li><li><strong>Warfarin </strong>— clarithromycin may enhance the effect of warfarin. <ul><li>Increase monitoring of the international normalized ratio (INR) when both drugs are used (particularly in elderly people), and adjust the warfarin dose accordingly. </li></ul></li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are <em>not</em> required during or after a course of clarithromycin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">FSRH, 2017</a>].<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> <hyperlink-marker innertext=\"Contraception - combined hormonal methods\" refid=\"-494585\"></hyperlink-marker>and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>For a complete list of possible drug interactions of clarithromycin, </strong>see the <a data-hyperlink-id=\"40ec65d5-2d3d-46c6-a3a8-a98f01110425\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"cf6a8caf-9ccd-4adf-9777-a98f0111044b\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field b13479b5-3a47-4ad7-9f7c-0037fc2ede41 --><!-- end item 9de11e99-0c5f-4956-9f75-44f87b635ecf -->","subChapters":[]},{"id":"46b2cfa9-c173-5801-a98b-7d53dd689172","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field d2a38271-4e6d-45e4-87e8-1474dc3e8c89 --><h3>Can clarithromycin be used during pregnancy and breastfeeding?</h3><!-- end field d2a38271-4e6d-45e4-87e8-1474dc3e8c89 -->","summary":"","htmlStringContent":"<!-- begin item e377278e-ed47-4a1a-9dba-5a1e230d8738 --><!-- begin field c75539fe-a49e-4000-a93a-8d4c3e38ec5b --><ul><li><strong>Pregnancy</strong><ul><li>The available data for clarithromycin do not suggest an increased risk of congenital malformation, but the possibility cannot be excluded [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">UKTIS, 2017b</a>].</li><li>The manufacturer advises that the use of clarithromycin is not advised in pregnancy, particularly in the first trimester, unless the potential benefit outweighs the risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>].</li></ul></li><li><strong>Breastfeeding</strong><ul><li>Clarithromycin is excreted into human breast milk. Epidemiologic evidence indicates that the risk of hypertrophic pyloric stenosis in infants might be increased by use of maternal macrolides, especially in infants exposed in the first 2 weeks after birth [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Fenner, 2016a</a>].</li><li>The manufacturer advises that the use of clarithromycin is not advised for breastfeeding women unless the potential benefit outweighs the risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>].</li></ul></li></ul><!-- end field c75539fe-a49e-4000-a93a-8d4c3e38ec5b --><!-- end item e377278e-ed47-4a1a-9dba-5a1e230d8738 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}